Galecto Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Galecto Inc
Access all reports
Galecto Inc. is a clinical-stage biotechnology company primarily focused on the development of small molecule therapeutics aimed at critical aspects of cancer and fibrotic diseases. Their research and development efforts are centered around the inhibition of galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins that play a pivotal role in the progression of these conditions. Galecto's portfolio includes GB0139, designed for treating Idiopathic Pulmonary Fibrosis (IPF), a serious progressive fibrotic lung disease; GB1211, a selective oral small molecule inhibitor of galectin-3 for various oncology indications and liver cirrhosis; and GB2064, targeting LOXL2 for the treatment of myelofibrosis. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
đșđž United States